D.E. Shaw & Co
NWBO

D.E. Shaw & Co’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

D.E. Shaw & Co’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-35,775
Closed -$52K – 3743
2016
Q1 		$52K Buy
35,775
+14,780
+70% +$29.2K ﹤0.01% 3333
2015
Q4 		$67K Sell
20,995
-62,481
-75% -$300K ﹤0.01% 3707
2015
Q3 		$522K Buy
83,476
+14,978
+22% +$140K ﹤0.01% 3033
2015
Q2 		$680K Buy
68,498
+55,392
+423% +$485K ﹤0.01% 2973
2015
Q1 		$97K Sell
13,106
-1,566
-11% -$10.5K ﹤0.01% 3528
2014
Q4 		$78K Sell
14,672
-11,053
-43% -$56.6K ﹤0.01% 3921
2014
Q3 		$129K Sell
25,725
-115,672
-82% -$711K ﹤0.01% 3956
2014
Q2 		$949K Buy
+141,397
New +$900K ﹤0.01% 2992

Other funds holding NWBO

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

D.E. Shaw & Co's NWBO Position: Q2 2016 in Review

D.E. Shaw & Co sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q2 2016, closing a stake of 35,775 shares — an estimated $52K sold.

D.E. Shaw & Co first reported a position in NWBO in Q2 2014 and held it in 8 quarters. The position peaked at $949K in Q2 2014. 64 funds tracked by Wall St. Rank hold NWBO as of Q2 2016.

  • D.E. Shaw & Co reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q2 2016 after selling out during the quarter.
  • D.E. Shaw & Co sold 35,775 Northwest Biotherapeutics, Inc. Common stock shares in Q2 2016, an estimated $52K.
  • D.E. Shaw & Co first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q2 2014 and held it in 8 quarters.
  • D.E. Shaw & Co's Northwest Biotherapeutics, Inc. Common stock position peaked at $949K in Q2 2014.
  • 64 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q2 2016.

Based on D.E. Shaw & Co's 13F filing for Q2 2016, filed 15 Aug 2016.